Got the distinct feeling that webinar was for the potential partners watching. Great detail provided by Donna and Mukesh. 008 really has corralled some compelling clinical data now that is going to be very very hard for interested parties to just walk away from. 008 always existed to ramp up the DMOAD data to inform partnership discussions (and TGA provisional approval applications) and boy, has it delivered. They may even come out of it with a pathway to DMOAD on the label from the FDA after Para_002. What a result that would be.
Ann: iPPS Increases Cartilage Thickness in Phase 2 Trial, page-68
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 29.5¢ | $89.62K | 294.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20607 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 16773 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |